Click on location tab to see list of dates and locations of programs.

How Do I Register?

Registration links are available on the tab labeled "LOCATION." Please select the city where you would like to attend, and you will be directed to the registration page.
****Please make sure your 'pop-up' blocker is disabled****



Statement of Need
Approximately 51,000 new cases of cancer of the kidney and renal pelvis will be diagnosed in the United States in 2007. Patient prognosis varies considerably based on the stage of the disease at diagnosis. For patients who are diagnosed with local disease, 5-year survival rates reach almost 90%. Nephrectomy is the standard of care for local renal cell carcinoma (RCC). However, because RCCs remain clinically silent for much of their natural history, 30% of patients present with metastatic disease. Another 30% of patients who have undergone apparent curative resection of their primary tumor develop metastases. Median survival for patients with advanced or metastatic disease is 6-12 months, with a 2-year survival rate of 10%-20%.

For the past 20 years, cytokine therapy has been the mainstay of treatment for metastatic RCC, despite its toxicity, low response rate, and short survival benefit (only months). The potential for immunotherapy has been demonstrated with occasional spontaneous and dramatic remissions, but the poor outcomes experienced by the majority of patients with metastatic RCC underscore the need for more effective treatment. Because of an expanding understanding of the genetic and molecular basis of RCC, more than 80 new compounds are under development for treatment of advanced RCC. In particular, small molecules and monoclonal antibodies (MoAbs) that target and inhibit key signaling pathways involved in tumor growth, survival, and angiogenesis have demonstrated clinical benefit or are undergoing testing against standard cytokine therapy. This activity will review the results obtained by current therapeutic strategies as a backdrop to a detailed discussion of the clinical potential of current and emerging targeted agents for the treatment of RCC.



Target Audience
This activity is designed for oncologists, physicians, nurses, and other health care professionals interested in recent advances in the treatment of patients with renal cell carcinoma.


Educational Objectives
After participating in this educational activity, attendees should be able to:

1. Describe the aberrant signaling pathways characteristic of RCC.
2. Discuss the safety and efficacy of recently approved novel multitargeted agents for RCC.
3. Discuss recent clinical trials investigating the safety and efficacy of MoAbs in the treatment of RCC.
4. Describe recent clinical trials investigating the safety and efficacy of novel agents targeting single pathways for the treatment of RCC.

Method of Participation
This interactive dinner discussion/presentation forum, including key abstracts presented at the 43rd American Society of Clinical Oncology Annual Meeting, will utilize multiple methods of participation to engage attendees and enhance the learning process.

Accreditation
Physicians: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the Essential Areas and policies of the ACCME.

The CBCE designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.

Nurses: The CBCE™ (The Center for Biomedical Continuing Education) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The CBCE designates this educational activity for 1.5 contact hours. Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.


Certificate
The Evaluation and Request for Credit Form must be completed and returned to the CBCE following this activity to obtain credit. Participants will receive their certificate 4-6 weeks after after the CBCE receives their form.

Acknowledgement of Commercial Support
The CBCE gratefully acknowledges the educational grants received from multiple commercial supporters. To date, we have received educational grants from Genentech BioOncology, Novartis Pharmaceuticals Corporation, and Pfizer Oncology. Please visit www.thecbce.com for a current list of supporters.

Americans With Disabilities Act (ADA)
The CBCE fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of support services, please notify the CBCE staff at the registration desk or in the meeting room in order to receive service.

Educational Inquiries
For further information, please contact the CBCE, 1707 Market Place Blvd., Suite 370, Irving, Texas 75063; Telephone: (214) 260-9024; Fax: (214) 260-0509; E-mail: info@thecbce.com.

Disclaimer
The content and views presented in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of the CBCE, Genentech BioOncology, Novartis Pharmaceuticals Corporation, or Pfizer Oncology. This material has been prepared based on a review of multiple sources of information, but is not exhaustive of the subject matter. Participants are advised to critically appraise the information presented, and are encouraged to consult the available literature on any product or device mentioned in this program.

Disclosure of Unlabeled Uses
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the Physicians' Desk Reference.

Disclosure of Financial Relationships With Any Commercial Interest
As a provider accredited by the ACCME, it is the policy of the CBCE to require that everyone who is in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest, and identify and resolve all conflicts of interest prior to the educational activity. The CBCE defines "relevant financial relationships" as any amount occurring within the past 12 months.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (eg, stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. The CBCE considers relationships of the person involved in the educational activity to include financial relationships of a spouse or partner.

Faculty who refuse to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the educational activity. For an individual with no relevant financial relationship(s), the participants must be informed that no relevant financial relationship(s) exists.


Disclosure of Potential Conflicts of Interest
The CBCE assesses conflicts of interest with its faculty, planners, and managers of CBCE activities. Identified conflicts of interest are thoroughly evaluated by the Planning Committee for fair balance, scientific objectivity relative to studies utilized in this activity, and patient-care recommendations. The CBCE is committed to providing its learners with high-quality, unbiased, and state-of-the-art education.

The following faculty have reported real or apparent conflicts of interest, and these conflicts have been resolved through a peer-review process:


Other
Michael B. Atkins, MD
Consultant
Antigenics Inc.
Bayer Pharmaceuticals Corporation
Genentech, Inc.
Novartis Pharmaceuticals Corporation

Ronald Bukowski, MD
Consultant
Antigenics Inc.
Bayer Pharmaceuticals Corporation
Genentech, Inc.
Pfizer Inc.
Grant/Research Support
Bayer Pharmaceuticals Corporation
Pfizer Inc.
Wyeth Pharmaceuticals
Honoraria
Bayer Pharmaceuticals Corporation
Genentech, Inc.
Novartis Pharmaceuticals Corporation
Onyx Pharmaceuticals, Inc.
Pfizer Inc.
Wyeth Pharmaceuticals

Robert Figlin, MD
Consultant
Keryx Biopharmaceuticals, Inc.
Pfizer Inc.
Wyeth Pharmaceuticals
Grant/Research Support
Amgen Inc.
GlaxoSmithKline
Keryx Biopharmaceuticals, Inc.
Pfizer Inc.
Wyeth Pharmaceuticals

Robert J. Motzer, MD
Grant/Research Support
Genentech, Inc.
Novartis Pharmaceuticals Corporation
Pfizer Inc.
Wyeth Pharmaceuticals

Jeffrey A. Sosman, MD
Consultant
Bayer Pharmaceuticals Corporation
Genentech, Inc.
Wyeth Pharmaceuticals


Other
The CBCE receives educational grants from the pharmaceutical industry and other commercial sources. Companies providing grants to the CBCE include the commercial supporter of this activity as well as the manufacturer(s) of certain drugs and/or devices discussed in this activity.

Staff Disclosure
The CBCE staff have declared they have no financial relationships that require disclosure.